Elucid vs Qure.ai

Elucid's cleared product quantifies coronary plaque to support clinicians, and its Lesion Inspection Tool for coronary and carotid plaque became commercially available in April 2026. A cardiology or vascular imaging group is the buyer. An emergency radiology service buys Qure for head CT triage with qER, cleared in June 2020, and for pneumothorax and effusion triage with qXR-PTX-PE, cleared in August 2023. A lung nodule program adds qXR-LN, cleared for adult frontal chest radiographs, and qCT LN Quant for volumetry, and qCT Lung received a 510(k) decision in September 2026. Qure says its TB screening received WHO endorsement in 2021, and the ten openFDA records for Qure include no TB screening product. An independent evaluation of twelve TB products measured qXR v3 at 95.5% sensitivity and 48.7% specificity at one threshold, which is the evidence a TB program outside the US would weigh.